# Nuformix excited as it moves focus to NXP002 and NXP004 programmes

- Link: https://www.directorstalkinterviews.com/nuformix-excited-as-it-moves-focus-to-nxp002-and-nxp004-programmes/4121127409
- Published: 2023-09-19T07:29:21+01:00
- Author: Ethan Davis

**Nuformix plc** ([LON:NFX](https://www.directorstalkinterviews.com/company/nuformix-plc/nfx.l))
Executive Director Dan Gooding joins DirectorsTalk to discuss an update on its NXP001
exclusive licensing agreement.

In this interview Dr Dan Gooding outlines what the revised agreement covers, explains
what it means for Nuformix and how it will benefit from NXP001 now and in the future,
progressing its core NXP002 and NXP004 programmes and how Dan sees the outlook for
the company.

**Nuformix plc** ([LON:NFX](https://www.directorstalkinterviews.com/company/nuformix-plc/nfx.l))
is a pharmaceutical development company targeting unmet medical needs in fibrosis
and oncology using drug repurposing

The company uses their expertise in discovering, developing and patenting novel 
drug forms with improved physical properties, to develop new products in new indications
that are differentiated from the original by way of: dosage, delivery route or presentation,
thus creating new and attractive commercial opportunities.

Share on:
